Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Understanding the benefits of early treatment for HIV is crucial for managing the disease effectively. Starting treatment soon after diagnosis not only preserves health but also enhances the quality ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...

When diagnosed with HIV, the timing of treatment initiation can significantly impact long-term health outcomes and quality of life. Medical experts increasingly advocate for immediate treatment ...

Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...